



Suboxone[®] (buprenorphine/naloxone) – First-time generic

- On February 20, 2019, [Alvogen](#) and [Dr. Reddy's](#) launched [AB-rated](#) generic versions of Indivior's [Suboxone \(buprenorphine/naloxone\)](#) sublingual film.
 - In addition, Sandoz launched [Indivior's](#) authorized generic version of Suboxone.
 - Mylan received FDA approval of an [AB-rated](#) generic version of Suboxone on June 14, 2018. Launch plans are pending.
- Suboxone is approved for treatment of opioid dependence.
 - Suboxone should be used as part of a complete treatment plan that includes counseling and psychosocial support.
- Buprenorphine/naloxone is also available generically as a [sublingual tablet](#), a brand sublingual tablet ([Zubsolv[®]](#)) and a brand buccal film ([Bunavail[®]](#)) that all carry the same indication as Suboxone sublingual film.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.